Welcome to our dedicated page for MAIA Biotechnology news (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.
MAIA Biotechnology Inc. (MAIA) is a clinical-stage biopharmaceutical company pioneering targeted cancer therapies through novel telomere science and immune-oncology research. This page provides investors and researchers with verified updates on MAIA's therapeutic advancements, corporate developments, and clinical progress.
Access timely announcements including clinical trial milestones, regulatory updates, financial reports, and strategic partnerships. Our curated news collection offers comprehensive insights into MAIA's diversified pipeline and R&D strategy while maintaining strict compliance with financial disclosure standards.
Key updates cover developments across MAIA's therapeutic programs, including its telomere-targeting THIO initiative, partnership announcements, and progress reports from dedicated research subsidiaries. Content is organized for quick scanning while maintaining scientific accuracy for both professional and non-specialist audiences.
Bookmark this page for streamlined access to MAIA's latest verified developments. For complete investment information, always consult official SEC filings alongside these news resources.
MAIA Biotechnology (NYSE American: MAIA) has received FDA Fast Track designation for ateganosine, its first-in-class small molecule treatment for non-small cell lung cancer (NSCLC). The drug, currently in a pivotal Phase 2 THIO-101 clinical trial, has shown promising results with a median overall survival of 17.8 months, significantly outperforming standard treatments that typically achieve 5-6 months survival.
Ateganosine targets telomere structure in cancer cells and works through telomerase-mediated action to reverse resistance to immune checkpoint inhibitors. The company is targeting a $34.1 billion NSCLC market that is projected to reach $68.8 billion by 2033. If successful, MAIA could receive accelerated FDA approval as early as next year.
MAIA Biotechnology (NYSE American: MAIA) announced the publication of preclinical data for its second-generation ateganosine prodrugs platform in Nucleic Acids Research journal. The study focuses on novel telomere-targeting dual-pharmacophore dinucleotide prodrugs for cancer treatment.
The company has developed over 80 ateganosine-like compounds and nominated two key candidates: MAIA-2021-20 (lead) and MAIA-2022-12 (backup). The research demonstrated that these compounds, when combined with immune checkpoint inhibitors, showed superior anticancer efficacy and stronger host immune-memory responses compared to monotherapies. MAIA plans to advance at least one candidate to human clinical trials following completion of required studies.
MAIA Biotechnology (NYSE American: MAIA) has announced the dosing of its first patient in Taiwan for the expansion phase of the THIO-101 Phase 2 trial, evaluating ateganosine in advanced non-small cell lung cancer (NSCLC). The trial focuses on heavily pre-treated third-line NSCLC patients who previously failed checkpoint inhibitors and chemotherapy treatments.
The study includes two treatment arms: ateganosine with cemiplimab (Libtayo®) and ateganosine monotherapy. Current data shows median overall survival of 17.8 months for third-line treatment patients, significantly exceeding the typical 5-6 months survival with chemotherapy. The NSCLC market, valued at $34.1B in 2024, is projected to reach $68.8B by 2033 with an 8.1% CAGR.
MAIA Biotechnology (NYSE American: MAIA) announced two upcoming poster presentations at the 49th Federation of European Biochemical Societies (FEBS) 2025 Congress in Istanbul, Turkey, scheduled for July 5-9, 2025. The presentations will focus on the company's telomere-targeting cancer therapeutics.
The first poster, presented by Dr. Z. Gunnur Dikmen, will discuss how RiboTHIO and THIO work synergistically with radiotherapy and immune checkpoint blockade in lung tumor treatment. The second poster, presented by Gamze Tuna, will explore the effects of novel telomerase-mediated compounds on DNA damage and repair in A549 cells.
The company also reported that its THIO-101 Phase 2 clinical trial for ateganosine in non-small cell lung cancer (NSCLC) demonstrated a median overall survival of 17.8 months in heavily pre-treated patients, based on May 15, 2025 data.
MAIA Biotechnology (NYSE American: MAIA) has strengthened its Scientific Advisory Board by appointing two leading HCC specialists, Dr. Claudia Fulgenzi and Dr. David J. Pinato. The appointments come as MAIA prepares for a Phase 2 clinical trial of its lead candidate ateganosine (THIO) in hepatocellular carcinoma (HCC).
The company expects to begin patient enrollment in the HCC trial by year-end, leveraging its 2022 FDA Orphan Drug Designation for ateganosine in HCC treatment, which could provide up to seven years of market exclusivity. Both appointees bring extensive expertise in liver cancer research and immunotherapy, with Dr. Pinato serving as Director of Developmental Cancer Therapeutics at Imperial College London and Dr. Fulgenzi specializing in immune-oncology at Imperial College London.